Pfizer completes acquisition of injectable drugmaker Hospira

SHARE Pfizer completes acquisition of injectable drugmaker Hospira

Pfizer said it has completed its acquisition of Lake Forest-based Hospira. | AP file photo

NEW YORK — The drugmaker Pfizer says it has completed its roughly $15 billion purchase of Lake Forest-based Hospira, a maker of injectable drugs and infusion devices, expanding its product offerings in a growing medical market.

The deal, first announced in February, gives Pfizer a leading position in the global market for injectable drugs, including a new class of lower-cost biotech drugs known as biosimilars. Earlier this year the Food and Drug Administration approved the first biosimilar for the U.S. market, a cheaper version of Amgen’s anti-infection drug Neupogen.

Hospira already markets several biosimilar drugs in Europe and Australia. For decades, biotech drugs faced no generic competition in the U.S. because the FDA lacked a system for approving lower-cost versions.

Global sales of biosimilars are expected to reach $20 billion by 2020, according to Pfizer. The company predicts the combination with Hospira will generate $800 million in cost savings by 2018.

New York-based Pfizer Inc. makes the arthritis pill Celebrex, Prevnar pneumococcal vaccines and the fibromyalgia drug Lyrica.

The Latest
Agnieszka Rydzewski es acusada de solicitar el asesinato de Arturo Cantú, quien presuntamente fue asesinado a tiros a principios de esta semana por Anthony Calderón en un triángulo amoroso en los suburbios del suroeste.
Al dictar la sentencia, la jueza Virginia Kendall le dijo a Janice Weston: “Es muy preocupante. Tuviste unos momentos en los que sabías que era ilegal y pudiste irte”.
José Torres, de 34 años, falleció en el Centro Médico de la Universidad de Chicago el sábado por la tarde, según informó la policía.
Joseph Weiss admitted lying about his brother’s ties to the late Chicago mobster Frank ‘The German’ Schweihs.